Table 4. Factor associated with overall survival.
| Variables | n/N | (%) | Cox regression analysis | |||
|---|---|---|---|---|---|---|
| HR | 95% CI of HR | P | ||||
| Sex | 0.196 | |||||
| Female (ref.) | 2/33 | (6) | 1.00 | – | ||
| Male | 8/48 | (17) | 2.78 | 0.59–13.10 | ||
| Age | 0.979 | |||||
| > 51 (ref.) | 5/40 | (13) | 1.00 | – | ||
| ≤ 51 | 5/41 | (12) | 1.02 | 0.29–3.52 | ||
| Stage | 0.906 | |||||
| Stage II (ref.) | 2/21 | (10) | 1.00 | – | ||
| Stage III | 5/38 | (13) | 1.41 | 0.27–7.26 | ||
| Stage IVA | 3/22 | (14) | 1.44 | 0.24–8.63 | ||
| NLR at pre-CCRT | 0.940 | |||||
| Low (ref.) | 5/40 | (13) | 1.00 | – | ||
| High | 5/41 | (12) | 0.95 | 0.28–2.30 | ||
| ΔNLR at end-CCRT from pre-CCRT | 0.506 | |||||
| Decrease (ref.) | 1/15 | (7) | 1.00 | - | ||
| Increase | 9/66 | (14) | 2.02 | 0.26–15.91 | ||
| ΔNLR at end-CCRT from pre-CCRT | NA | |||||
| Decrease (ref.) | 0/21 | (0) | - | - | ||
| Increase | 10/60 | (17) | - | - | ||
Abbreviations: ref., reference group; HR, hazard ratio; aHR, adjusted hazard ratio; 95%CI, 95% confidence interval; NA, not applicable; NLR, neutrophil to lymphocyte ratio; CCRT, concurrent chemoradiotherapy; AC, adjuvant chemotherapy.